DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

LaunchTrends: Tafinlar and Mekinist (Malignant Melanoma) (Wave 1) US 2013

LaunchTrends®: Tafinlar/Mekinist is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Tafinlar (GlaxoSmithKline’s dabrafenib) and Mekinist (GlaxoSmithKline’s trametinib).
LaunchTrends®: Tafinlar/Mekinist measures the impact of these new agents on the unresectable/metastatic malignant melanoma market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. These reports evaluate physicians’ current awareness and perception of Tafinlar and Mekinist relative to other currently available therapies for unresectable/metastatic malignant melanoma, current and anticipated use of Tafinlar and Mekinist, and promotional activity of Tafinlar and Mekinist.

Questions Answered in This Report:

  • Understand awareness of and familiarity with Dabrafenib and Trametinib among Medical Oncologists

  • Understand the perceived clinical advantages and disadvantages of Dabrafenib compared to other marketed agents used in treating Metastatic Melanoma

  • Understand the perceived clinical advantages and disadvantages of Trametinib compared to other marketed agents used in treating metastatic melanoma

  • Understand where Dabrafenib and Trametinib are expected to fit in the treatment algorithm for patients with metastatic melanoma

  • Track the trial, adoption, and usage trends including anticipated future trends for the treatment of metastatic melanoma

  • Collect information on the promotional messages and activities being employed by GlaxoSmithKline

  • Capture interest and familiarity of next generation therapies in development


Sample Frame & Methodology:

- This report will include responses from a random sample of 100 Medical Oncologists

- A qualitative follow up arm includes telephone interviews conducted with a sub-set of 15 survey respondents

To qualify for participation, Medical Oncologists must meet the following criteria:

- In practice between 2 and 30 years

- Minimum of 50 patients with Melanoma personally treated over the last year

- More than 50% of time spent in clinical practice


- Final report in powerpoint format (from each wave)

- Complete set of frequency tables, summary statistics, and cross tabulations (each wave)

- Copies of telephone interviews (as audio files; blinded)

- Proprietary question slide deck and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Product Coverage:

Yervoy (ipilimumab), Temodar, Zelboraf (venurafenib), Dacarbazine, Paclitaxel

Companion Reports - BioTrends:

- TreatmentTrends®: Melanoma US

- TreatmentTrends®: Melanoma EU

- LaunchTrends®: Yervoy & Zelboraf US

Companion Reports - Decision Resources:

- Pharmacor Melanoma

- Physician & Payer Forum (EU)

- Patient Flow Model: Melanoma